9714 related articles for article (PubMed ID: 14732881)
1. Melanoma vaccines: achievements and perspectives.
Brichard VG; Gérard C
Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
4. [Vaccine strategies against melanoma].
Ghiringhelli F; Zitvogel L
Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
[TBL] [Abstract][Full Text] [Related]
5. Recent advances and hurdles in melanoma immunotherapy.
Jandus C; Speiser D; Romero P
Pigment Cell Melanoma Res; 2009 Dec; 22(6):711-23. PubMed ID: 19735459
[TBL] [Abstract][Full Text] [Related]
6. Melanoma cancer vaccines and anti-tumor T cell responses.
Vujanovic L; Butterfield LH
J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell vaccination as a treatment modality for melanoma.
Eubel J; Enk AH
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
[TBL] [Abstract][Full Text] [Related]
9. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Sosman JA; Sondak VK
Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
[TBL] [Abstract][Full Text] [Related]
10. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
11. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
12. Rational development of tumour antigen-specific immunization in melanoma.
Gajewski TF; Fallarino F
Ther Immunol; 1995 Aug; 2(4):211-25. PubMed ID: 9358613
[TBL] [Abstract][Full Text] [Related]
13. Melanoma antigens and targets for vaccination.
Kang N; Truman H; Sanders R; Kupsch J
Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
[TBL] [Abstract][Full Text] [Related]
14. Vaccination: role in metastatic melanoma.
Pilla L; Valenti R; Marrari A; Patuzzo R; Santinami M; Parmiani G; Rivoltini L
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1305-18. PubMed ID: 16925496
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
Sondak VK; Sabel MS; Mulé JJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
[TBL] [Abstract][Full Text] [Related]
16. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
Hsueh EC; Morton DL
Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
[TBL] [Abstract][Full Text] [Related]
17. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
18. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
Campoli M; Ferrone S
Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of melanoma.
Hersey P
Asia Pac J Clin Oncol; 2010 Mar; 6 Suppl 1():S2-8. PubMed ID: 20482529
[TBL] [Abstract][Full Text] [Related]
20. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide.
Balasse E; Gatouillat G; Patigny D; Andry MC; Madoulet C
Vaccine; 2009 Oct; 27(44):6107-9. PubMed ID: 19686694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
